Specialty Pharmacy

Biosimilars are an estimated 30% cheaper than branded biologics

For the first time, an oral therapy has been proven to reduce the risk of developing clinically definite multiple sclerosis in patients with a clinically isolated syndrome.

Assessing a patient's sense of balance and hearing ability may be an aid in diagnosing psoriatic arthritis.

Combined specialty pharmacy organization poised to advance the field amid changing health care landscape.

Organization warns disease is spreading faster than it can be contained.

A prognostic disease marker that often occurs in patients with triple-negative breast cancer may lead to development of a medication to close a therapeutic gap in targeted cancer treatment.

Countries at highest risk for Ebola transmission identified through animal migration patterns.

Commentary stresses importance of safe removal of protective gear among those caring for infected patients.

Data indicates that a simeprevir-based therapy is efficacious in patients with HIV-1/HCV genotype 1 coinfection.

Bill Barre, RPh, vice president of business development at MedImpact Healthcare Systems, how specialty pharmacies can meet the demands of consumerism in the new era of prescription fulfillment.

Ebola epidemic expected to surge, though relief workers are already overwhelmed by increasing patient volume.

Increased salt intake may magnify the risk of relapses in patients with multiple sclerosis.

Progress made on new Ebola drugs as US government pledges resources to West Africa.

Scientists discover how to stop cells from attacking healthy tissue.

New treatment option for treatment of orthostatic dizziness.

A recent study published in the journal Hepatology indicates that as many as 11% of baby boomers had a positive test result for presence of anti-HCV antibodies.

FDA decision expected by early 2015.

A recent meta-analysis published in the journal Plos One indicates a potential link between breast cancer and use of a common blood pressure medication, but a closer look tells a different story.

Humanitarian organization says world leaders are failing to address epidemic.

Experimental vaccine could begin clinical trials in humans in early 2015.

Centers for Medicare & Medicaid Services report projects health expenditures to grow at an average annual rate of 5.7% through 2023.

Pembrolizumab is the first drug approved that blocks the PD-1 cellular pathway.

Study finds HIV suppression reduces hepatitis C viral replication over time.

John Musil, PharmD, chief executive officer and founder of Avella Specialty Pharmacy, discusses how the specialty pharmacy model is evolving.

Director of Centers for Disease Control and Prevention cautions that outbreak in West Africa is outpacing the response.

Experts at Johns Hopkins say ability to go off antiviral treatment for an extended period of time is a critical goal.

Elelyso offers pediatric patients with Type 1 Gaucher disease another treatment option.

National Institutes of Health and GlaxoSmithKline will conduct safety evaluations on collaborative treatment in human subjects starting this week.

New treatments drive growth forecast.